Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. MEDS Chinese Medicine
  4. Vol 6, Issue 1, 2024

Research Progress on the Mechanism of Cardiotoxicity Caused by Doxorubicin and Its Treatment by Traditional Chinese Medicine

Download as PDF

DOI: 10.23977/medcm.2024.060120 | Downloads: 7 | Views: 76

Author(s)

Xuhao Li 1, Jing Ma 2

Affiliation(s)

1 Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, 712046, China
2 First Affiliated Hospital of Air Force Military Medical University, Xi'an, Shaanxi, 710032, China

Corresponding Author

Jing Ma

ABSTRACT

Doxorubicin is a widely used antitumor drug, but its cardiotoxicity limits its clinical use. This paper reviews the main mechanisms of Doxorubicin causing cardiotoxicity, including topoisomerase IIβ, oxidative stress, mitochondrial function, calcium homeostasis, autophagy, and apoptosis, etc. It also introduces some novel targets and strategies, such as the CRTH2 receptor, the Nrf2 signaling pathway, the SIRTs family of proteins, and the progress of the research on the treatment of traditional Chinese medicine. This paper aims to provide new ideas and directions for the prevention and treatment of Doxorubicin cardiotoxicity.

KEYWORDS

Doxorubicin, cardiotoxicity, CRTH2, Nrf2, SIRTs, Chinese medicine

CITE THIS PAPER

Xuhao Li, Jing Ma, Research Progress on the Mechanism of Cardiotoxicity Caused by Doxorubicin and Its Treatment by Traditional Chinese Medicine. MEDS Chinese Medicine (2024) Vol. 6: 143-149. DOI: http://dx.doi.org/10.23977/medcm.2024.060120.

REFERENCES

[1] Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants [J]. Chin Med J (Engl), 2022, 135(5):584-590.
[2] Zhao H, Yu J, Zhang R, et al. Doxorubicin prodrug-based nanomedicines for the treatment of cancer [J]. Eur J Med Chem, 2023, 258:115612.
[3] He H, Wang L, Qiao Y, et al. Epigallocatechin-3-gallate pretreatment alleviates doxorubicin-induced ferroptosis and cardiotoxicity by upregulating AMPKalpha2 and activating adaptive autophagy[J]. Redox Biol, 2021, 48:102185.
[4] Khiati S, Dalla R I, Sourbier C, et al. Mitochondrial topoisomerase I (top1mt) is a novel limiting factor of doxorubicin cardiotoxicity [J]. Clin Cancer Res, 2014, 20(18):4873-4881.
[5] Galaris D, Barbouti A, Pantopoulos K. Iron homeostasis and oxidative stress: An intimate relationship[J]. Biochim Biophys Acta Mol Cell Res, 2019, 1866(12):118535.
[6] Liu C, Cai Z, Hu T, et al. Cathepsin B aggravated doxorubicin‑induced myocardial injury via NF‑kappaB signalling[J]. Mol Med Rep, 2020, 22(6):4848-4856.
[7] Singh M, Nicol A T, DelPozzo J, et al. Demystifying the Relationship Between Metformin, AMPK, and Doxorubicin Cardiotoxicity[J]. Front Cardiovasc Med, 2022, 9:839644.
[8] Wallace K B, Sardao V A, Oliveira P J. Mitochondrial Determinants of Doxorubicin-Induced Cardiomyopathy [J]. Circ Res, 2020, 126(7):926-941.
[9] Sritharan S, Sivalingam N. A comprehensive review on time-tested anticancer drug doxorubicin [J]. Life Sci, 2021, 278:119527.
[10] Jiao Y, Li Y, Zhang J, et al. RRM2 Alleviates Doxorubicin-Induced Cardiotoxicity through the AKT/mTOR Signaling Pathway[J]. Biomolecules, 2022, 12(2).
[11] Zhang Y, Liu S, Ma J L, et al. Apocynum venetum leaf extract alleviated doxorubicin-induced cardiotoxicity through the AKT/Bcl-2 signaling pathway[J]. Phytomedicine, 2022, 94:153815.
[12] Twomey J D, Kim S R, Zhao L, et al. Spatial dynamics of TRAIL death receptors in cancer cells[J]. Drug Resist Updat, 2015, 19:13-21.
[13] Zhao L, Zhang B. Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes [J]. Sci Rep, 2017, 7:44735.
[14] Yu W, Sun H, Zha W, et al. Apigenin Attenuates Adriamycin-Induced Cardiomyocyte Apoptosis via the PI3K/AKT/mTOR Pathway[J]. Evid Based Complement Alternat Med, 2017, 2017:2590676.
[15] Zuo S, Kong D, Wang C, et al. CRTH2 promotes endoplasmic reticulum stress-induced cardiomyocyte apoptosis through m-calpain [J]. EMBO Mol Med, 2018, 10(3).
[16] Chen Q M, Maltagliati A J. Nrf2 at the heart of oxidative stress and cardiac protection [J]. Physiol Genomics, 2018, 50(2):77-97.
[17] Wu W Y, Cui Y K, Hong Y X, et al. Doxorubicin cardiomyopathy is ameliorated by acacetin via Sirt1-mediated activation of AMPK/Nrf2 signal molecules[J]. J Cell Mol Med, 2020, 24(20):12141-12153.
[18] Wang S, Wang Y, Zhang Z, et al. Cardioprotective effects of fibroblast growth factor 21 against doxorubicin- induced toxicity via the SIRT1/LKB1/AMPK pathway[J]. Cell Death Dis, 2017, 8(8):e3018.
[19] Koleini N, Nickel B E, Wang J, et al. Fibroblast growth factor-2-mediated protection of cardiomyocytes from the toxic effects of doxorubicin requires the mTOR/Nrf-2/HO-1 pathway [J]. Oncotarget, 2017, 8(50):87415-87430.
[20] Liao Z Q, Jiang Y N, Su Z L, et al. Rutaecarpine Inhibits Doxorubicin-Induced Oxidative Stress and Apoptosis by Activating AKT Signaling Pathway [J]. Front Cardiovasc Med, 2021, 8:809689.
[21] Zhang Y, Ahmad K A, Khan F U, et al. Chitosan oligosaccharides prevent doxorubicin-induced oxidative stress and cardiac apoptosis through activating p38 and JNK MAPK mediated Nrf2/ARE pathway[J]. Chem Biol Interact, 2019, 305:54-65.
[22] Yu W, Chen C, Xu C, et al. Activation of p62-NRF2 Axis Protects against Doxorubicin-Induced Ferroptosis in Cardiomyocytes: A Novel Role and Molecular Mechanism of Resveratrol[J]. Am J Chin Med, 2022, 50(8):2103-2123.
[23] Gu J, Huang H, Liu C, et al. Pinocembrin inhibited cardiomyocyte pyroptosis against doxorubicin-induced cardiac dysfunction via regulating Nrf2/Sirt3 signaling pathway[J]. Int Immunopharmacol, 2021, 95:107533.
[24] Hsieh P L, Chu P M, Cheng H C, et al. Dapagliflozin Mitigates Doxorubicin-Caused Myocardium Damage by Regulating AKT-Mediated Oxidative Stress, Cardiac Remodeling, and Inflammation [J]. Int J Mol Sci, 2022, 23(17).
[25] Wang A J, Tang Y, Zhang J, et al. Cardiac SIRT1 ameliorates doxorubicin-induced cardiotoxicity by targeting sestrin 2[J]. Redox Biol, 2022, 52:102310.
[26] Wu S, Lan J, Li L, et al. Sirt6 protects cardiomyocytes against doxorubicin-induced cardiotoxicity by inhibiting P53/Fas-dependent cell death and augmenting endogenous antioxidant defense mechanisms[J]. Cell Biol Toxicol, 2023, 39(1):237-258.
[27] Peng K, Zeng C, Gao Y, et al. Overexpressed SIRT6 ameliorates doxorubicin-induced cardiotoxicity and potentiates the therapeutic efficacy through metabolic remodeling[J]. Acta Pharm Sin B, 2023, 13(6):2680-2700.
[28] Feng P, Yang Y, Liu N, et al. Baicalin regulates TLR4/IkappaBalpha/NFkappaB signaling pathway to alleviate inflammation in Doxorubicin related cardiotoxicity[J]. Biochem Biophys Res Commun, 2022, 637:1-8.
[29] El-Ela S, Zaghloul R A, Eissa L A. Promising cardioprotective effect of baicalin in doxorubicin-induced cardiotoxicity through targeting toll-like receptor 4/nuclear factor-kappaB and Wnt/beta-catenin pathways[J]. Nutrition, 2022, 102:111732.
[30] Hong H J, Liu J C, Chen P Y, et al. Tanshinone IIA prevents doxorubicin-induced cardiomyocyte apoptosis through Akt-dependent pathway[J]. Int J Cardiol, 2012, 157(2):174-179.
[31] Wang X, Li C, Wang Q, et al. Tanshinone IIA Restores Dynamic Balance of Autophagosome/Autolysosome in Doxorubicin-Induced Cardiotoxicity via Targeting Beclin1/LAMP1[J]. Cancers (Basel), 2019, 11(7).
[32] Lin J, Fang L, Li H, et al. Astragaloside IV alleviates doxorubicin induced cardiomyopathy by inhibiting NADPH oxidase derived oxidative stress [J]. Eur J Pharmacol, 2019, 859:172490.
[33] Luo L F, Guan P, Qin L Y, et al. Astragaloside IV inhibits adriamycin-induced cardiac ferroptosis by enhancing Nrf2 signaling [J]. Mol Cell Biochem, 2021, 476(7):2603-2611.
[34] Feng K, Liu Y, Sun J, et al. Compound Danshen Dripping Pill inhibits doxorubicin or isoproterenol-induced cardiotoxicity [J]. Biomed Pharmacother, 2021, 138:111531.

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 4205
Visits: 166108

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.